Heterozygous Familial Hypercholesterolemia (HeFH) Latest Advances
Find the Latest Research About Heterozygous Familial Hypercholesterolemia (HeFH)
Last Updated: 09/19/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2454 publications
Evaluating enlicitide decanoate: first oral PCSK9 inhibitor for the treatment of adults with hypercholesterolemia.
Journal: Expert opinion on pharmacotherapy
Published: September 08, 2026
Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis.
Journal: Journal of cardiovascular development and disease
Published: July 15, 2026
Lipoprotein apheresis: From familial hypercholesterolemia and elevated lipoprotein(a) to emerging roles in peripheral arterial and renal disease.
Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
Published: June 30, 2026
Bempedoic acid in real-world clinical practice: baseline and 8-week data from the Italian prospective, non-interventional MILOS study
Journal: Giornale italiano di cardiologia (2006)
Published: June 25, 2026
Genetic Spectrum of Familial Hypercholesterolemia in Russian North-West Registry: Focus on Correlation Between Clinical and Genetic Diagnosis.
Journal: Journal of cardiovascular development and disease
Published: June 19, 2026
Severe Hyperlipidemia and Multifocal Atherosclerosis With Negative Genetic Testing for Familial Hypercholesterolemia: A Case Report.
Journal: Cureus
Published: June 08, 2026
Severe Multivessel Coronary Artery Disease in an Adolescent With Genetic Dyslipidemia.
Journal: JACC. Case reports
Published: June 03, 2026
Erratum to "ApoB/LDL-C discordance as a predictor of atherosclerotic cardiovascular disease in genetically confirmed heterozygous familial hypercholesterolemia: A hypothesis-generating cohort study" [J Clin Lipidol 20(3) (2026) 490-503].
Journal: Journal of clinical lipidology
Published: May 27, 2026
In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia.
Journal: The New England journal of medicine
Published: May 26, 2026
Last Updated: 09/19/2026